Aztron Medtech, a privately held orthopedic device company, recently announced that more than 100 clinical procedures have been performed in the United States using its TendMIN Minimally Invasive Achilles Tendon Repair System, marking a significant milestone in the system’s continued clinical adoption.
The 100th U.S. TendMIN procedure was performed by Dr. Brian Burgess, DPM, a board-certified podiatric surgeon.
“Reaching 100 U.S. cases is an important milestone for both clinical adoption and the continued advancement of minimally invasive Achilles tendon repair,” said Yi-Hsi (Ben) Huang, CEO of Aztron Medtech. “This achievement reflects rapidly growing surgeon utilization of the TendMIN system and its ability to deliver a consistent, minimally invasive repair that aligns with modern expectations for patient recovery and surgical efficiency.”
The TendMIN system is designed to enable percutaneous Achilles tendon repair through an incision of approximately 1 centimeter or less, allowing surgeons to perform a robust repair while minimizing soft tissue disruption. Published literature on minimally invasive and percutaneous Achilles tendon repair techniques has demonstrated potential benefits, including reduced infection risk, fewer wound complications, and accelerated recovery compared to traditional open repair approaches (Wang et al., 2012, Wang et al., 2024).
Building on this momentum, Aztron Medtech is continuing to expand surgeon training initiatives, support ongoing clinical data collection, and broaden access to the TendMIN system across the U.S. foot and ankle, sports medicine and orthopedic markets.
